Grant ID RP130651
Awarded On December 05, 2012
Title MAPK4 Activates AR and Promotes Castration-Resistant Prostate Cancer
Program Academic Research
Award Mechanism Individual Investigator
Institution/Organization Baylor College of Medicine
Principal Investigator/Program Director Feng Yang
Cancer Sites Prostate
Contracted Amount $579,578
Lay Summary

Prostate cancer is the most common cancer and the second leading cause of cancer death in American men. Activated Androgen Receptor (AR) is essential for the growth/survival of human prostate cancer. Therefore, androgen-ablation therapy is a standard therapy for advanced and metastatic prostate cancer. However, most initially regressed prostate cancer will relapse and become castration-resistant prostate cancer (CRPC). Interestingly, most CRPCs maintain functional AR; therefore, AR remains a valid therapeutic target for CRPC. However, even with the best available androgen-blockage agents, including the recently FDA-approved Zytiga, there is still no cure for CRPC. Hormone-independent AR act...

Read More